David P. Carbone, MD, PhD, from the The Ohio State University Wexner Medical Center, discusses advances in the treatment of lung cancer.
David P. Carbone, MD, PhD, Professor, Division of Medical Oncology, Director, Thoracic Oncology Center, The James, The Ohio State University Wexner Medical Center, discusses advances in the treatment of lung cancer.
Recent advances in immunotherapy of lung cancer are probably the most exciting aspect of lung cancer therapy in the last few years, Carbone says. There is a large portion of patients who do not have immediately actionable lesions identified by current gene sequencing methods. Immunotherapy is potentially effective in these patients and could provide a way to improve outcome even in patients with EGFR and ALK mutations in combination with other treatments.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More